Physician profile
Jonathan C Kapp
NPI 1811253628
$5,477.84
in general payments reported to CMS, 2019-2025
28 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $275 · 2021: $1,177 · 2022: $1,156 · 2023: $272 · 2024: $518 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $969.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $962.26 | 2021-2025 | |
| Novo Nordisk INC | $844.81 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $400.19 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $396.51 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $278.23 | 2019-2022 | |
| Allergan, INC. | $265.01 | 2019-2020 | |
| Amgen INC. | $247.59 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $247.09 | 2019-2020 | |
| Lilly USA, LLC | $215.58 | 2019-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.43 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $87.97 | 2021 | |
| Astellas Pharma US INC | $77.53 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $62.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.36 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $25.41 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $24.49 | 2019 | |
| Vanda Pharmaceuticals INC. | $23.54 | 2022 | |
| Nevro Corp. | $21.85 | 2024 | Senza |
| Circassia INC. | $20.38 | 2019 | |
| Dexcom, INC. | $18.99 | 2024 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $17.27 | 2019 | |
| Lifescan, INC. | $17.17 | 2022 | |
| Daiichi Sankyo INC. | $17.14 | 2019 | |
| Exact Sciences Corporation | $16.04 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.46 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.35 | 2022 | |
| Gilead Sciences, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.